These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30548309)

  • 61. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
    Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
    Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ZnO/CNT@Fe
    Yousefi AM; Safaroghli-Azar A; Fakhroueian Z; Bashash D
    Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):735-745. PubMed ID: 32272856
    [TBL] [Abstract][Full Text] [Related]  

  • 64. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
    Farhadi E; Zaker F; Safa M; Rezvani MR
    Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
    Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes.
    Anusha ; Dalal H; Subramanian S; V P S; Gowda DA; H K; Damodar S; Vyas N
    Cell Death Dis; 2021 Mar; 12(3):259. PubMed ID: 33707419
    [TBL] [Abstract][Full Text] [Related]  

  • 68. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
    Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
    Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
    J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
    Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
    Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M
    J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.
    Wang H; Xie B; Kong Y; Tao Y; Yang G; Gao M; Xu H; Zhan F; Shi J; Zhang Y; Wu X
    Oncotarget; 2016 Apr; 7(14):18638-50. PubMed ID: 26942564
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells.
    Zeng C; Liu S; Lu S; Yu X; Lai J; Wu Y; Chen S; Wang L; Yu Z; Luo G; Li Y
    Mol Cancer; 2018 Aug; 17(1):130. PubMed ID: 30153828
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
    Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
    Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway.
    Yuan R; Chang J; He J
    Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):81-85. PubMed ID: 33040790
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nobiletin Promotes Megakaryocytic Differentiation through the MAPK/ERK-Dependent EGR1 Expression and Exerts Anti-Leukemic Effects in Human Chronic Myeloid Leukemia (CML) K562 Cells.
    Yen JH; Lin CY; Chuang CH; Chin HK; Wu MJ; Chen PY
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260160
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The potentiation of menadione on imatinib by downregulation of ABCB1 expression.
    Xiao FY; Zhou FJ; Yuan F; Kuang W; Zhou G; Zhou HH; Cao S
    Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):997-1004. PubMed ID: 32112424
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line.
    Bhutra S; Lenkala D; LaCroix B; Ye M; Huang RS
    PLoS One; 2014; 9(12):e115003. PubMed ID: 25506832
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia.
    Liu YY; Jiao WY; Li T; Bao YY
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8468-8475. PubMed ID: 31646577
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.
    Chorzalska A; Kim JF; Roder K; Tepper A; Ahsan N; Rao RSP; Olszewski AJ; Yu X; Terentyev D; Morgan J; Treaba DO; Zhao TC; Liang O; Gruppuso PA; Dubielecka PM
    Stem Cells Dev; 2017 May; 26(9):656-677. PubMed ID: 28103766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.